223 related articles for article (PubMed ID: 9340973)
1. [Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
Backe J; Gassel AM; Müller T; Schön S; Kaesemann H
Zentralbl Gynakol; 1997; 119(7):334-42. PubMed ID: 9340973
[TBL] [Abstract][Full Text] [Related]
2. [Effect of the proliferation rate on the course of node negative breast carcinoma].
Mitze M; Weikel W; Brumm C; Lippold R; Knapstein PG
Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):299-305. PubMed ID: 7657137
[TBL] [Abstract][Full Text] [Related]
3. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
Salvesen HB; Iversen OE; Akslen LA
Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
[TBL] [Abstract][Full Text] [Related]
4. The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.
Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; Mychalczak BR; McKee B; Hoskins WJ; Barakat RR
Cancer; 2002 Jul; 95(2):316-21. PubMed ID: 12124832
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of morphometric nuclear grade of endometrial carcinoma.
Salvesen HB; Iversen OE; Akslen LA
Cancer; 1998 Sep; 83(5):956-64. PubMed ID: 9731900
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
7. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
8. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
9. [The prognostic value of cathepsin D in endometrial carcinoma].
Köhler U; Langanke D; Sorger D; Martin R; Bilek K
Zentralbl Gynakol; 1995; 117(3):148-52. PubMed ID: 7740849
[TBL] [Abstract][Full Text] [Related]
10. [Multivariate analysis of prognostic factors in endometrial carcinoma].
Li B; Wu LY; Li SM; Zhang WH; Zhang R; Ma SK
Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
[TBL] [Abstract][Full Text] [Related]
11. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
12. 5-year survival rate in endometrial carcinoma stage I-II related to steroid receptor concentration, degree of differentiation, age and myometrial invasion.
Lindahl B; Fernö M; Gullberg B; Norgren A; Willén R
Anticancer Res; 1992; 12(2):409-12. PubMed ID: 1580559
[TBL] [Abstract][Full Text] [Related]
13. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma.
Baak JP; Snijders W; van Diermen B; van Diest PJ; Diepenhorst FW; Benraadt J
J Clin Oncol; 2003 Nov; 21(22):4214-21. PubMed ID: 14615450
[TBL] [Abstract][Full Text] [Related]
14. Clinical stage I and II endometrial carcinoma: multivariate analysis of prognostic factors.
Mammoliti S; Bruzzone M; Chiara S; Vidali A; Miglio L; Fontana V; Oliva C; Compora E; Giuntini P; Centonze M
Anticancer Res; 1992; 12(5):1415-8. PubMed ID: 1444199
[TBL] [Abstract][Full Text] [Related]
15. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
Fine BA; Valente PT; Feinstein GI; Dey T
Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438
[TBL] [Abstract][Full Text] [Related]
16. High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus.
Bonatz G; Frahm SO; Klapper W; Helfenstein A; Heidorn K; Jonat W; Krupp G; Parwaresch R; Rudolph P
Hum Pathol; 2001 Jun; 32(6):605-14. PubMed ID: 11431715
[TBL] [Abstract][Full Text] [Related]
17. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
18. Steroid hormone receptor content and lymph node status in endometrial cancer.
Morris PC; Anderson JR; Anderson B; Buller RE
Gynecol Oncol; 1995 Mar; 56(3):406-11. PubMed ID: 7705676
[TBL] [Abstract][Full Text] [Related]
19. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
20. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]